Breast cancer is the leading type of cancer diagnosed in women worldwide and requires predictive research models for preclinical drug development. Patient-derived xenograft (PDX) models provide a true representation of the human heterogeneity and can be used to test the efficacy of novel agents against drug resistance. The CrownBio PDX models of breast cancer collection consists of a wide range of models, including 17 triple negative breast cancer (TNBC) models as well as ER+, PR+, and HER2+ models.
Our Breast cancer Patient-derived xenograft models offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, Patient derived xenograft reflects the heterogeneity and diversity of the human patient population. A Breast cancer (PDX) model will give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio Breast cancer PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
Learn More at: https://models.crownbio.com/model/pdx/breast-cancer/